TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02055157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 111
Description: BMN 111 will be administered daily for 24 months in an open-label sequential dose adjustment fashion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 111
Description: BMN 111 will be administered daily for 24 months in an open-label sequential dose adjustment fashion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 111
Description: BMN 111 will be administered daily for 24 months in an open-label sequential dose adjustment fashion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 111
Description: BMN 111 will be administered daily for 24 months in an open-label sequential dose adjustment fashion.
Study: NCT00733499

Intervention type: DEVICE
Group type: OTHER
Intervention: LCS Complete Duofix
Description: Orthopaedic implant for total knee replacement with Duofix biological fixation surfaces

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LCS Complete Porocoat
Description: Orthopaedic implant for total knee replacement with Porocoat biological fixation surfaces
Study: NCT01382329

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated)
Description: Intramuscular injection into the musculus deltoideus or subcutaneous injection in the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated)
Description: Intramuscular injection into the musculus deltoideus or subcutaneous injection in the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated)
Description: Intramuscular injection into the musculus deltoideus or subcutaneous injection in the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated)
Description: Intramuscular injection into the musculus deltoideus or subcutaneous injection in the upper arm
Study: NCT04508608

Intervention type: DIAGNOSTIC_TEST
Intervention: Stress Gated blood pool SPECT
Description: After labeling of red blood cells in vivo, a sequential series of acquisition is carried out at rest and during increasing doses of dobutamine (5/10/15 μg / kg / min). The duration of acquisition is 300 seconds.~The acquisitions are carried out on dedicated cardiac gamma-camera with ultrafast Cadmium zinc telluride (CZT) detectors (DiscoveryNM530c, General electric Healthcare Israel, Israel)

Intervention type: DIAGNOSTIC_TEST
Intervention: Stress Gated blood pool SPECT
Description: After labeling of red blood cells in vivo, a sequential series of acquisition is carried out at rest and during increasing doses of dobutamine (5/10/15 μg / kg / min). The duration of acquisition is 300 seconds.~The acquisitions are carried out on dedicated cardiac gamma-camera with ultrafast Cadmium zinc telluride (CZT) detectors (DiscoveryNM530c, General electric Healthcare Israel, Israel)

Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamic SPECT
Description: The passage of a radiopharmaceutical bolus through the cavities of the heart and myocardium at rest and during infusion of adenosine at a dosage of 140 mcg / kg / min (for 4 minutes) is recorded.~At the peak of the stress test (after 2 minutes of administration of adenosine), a 5 ml bolus (dose 260-444 MBq) of 99mTc-methoxyisobutylisonitrile (MIBI) is administered at a rate of 1 ml / s. Immediately after the end of tracer administration, 30 ml of 0.9% sodium chloride (NaCl) is infused. A scintigraphic recording of the study begins 5 seconds before the administration of the radiopharmaceutical.~The next day, the study at rest is carried out. Scintigraphic images are recorded in tomographic mode with ECG synchronization for 600 s, at list mode.~The acquisitions are carried out on dedicated cardiac gamma-camera with ultrafast CZT detectors (DiscoveryNM530c, General electric Healthcare Israel, Israel)

Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamic SPECT
Description: The passage of a radiopharmaceutical bolus through the cavities of the heart and myocardium at rest and during infusion of adenosine at a dosage of 140 mcg / kg / min (for 4 minutes) is recorded.~At the peak of the stress test (after 2 minutes of administration of adenosine), a 5 ml bolus (dose 260-444 MBq) of 99mTc-methoxyisobutylisonitrile (MIBI) is administered at a rate of 1 ml / s. Immediately after the end of tracer administration, 30 ml of 0.9% sodium chloride (NaCl) is infused. A scintigraphic recording of the study begins 5 seconds before the administration of the radiopharmaceutical.~The next day, the study at rest is carried out. Scintigraphic images are recorded in tomographic mode with ECG synchronization for 600 s, at list mode.~The acquisitions are carried out on dedicated cardiac gamma-camera with ultrafast CZT detectors (DiscoveryNM530c, General electric Healthcare Israel, Israel)
Study: NCT01299519

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Maintenance
Description: Subjects in the weight maintenance arm will maintain a steady body weight (plus or minus 2% of initial body weight) for six months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: Half of the subjects in the weight loss arm will lose 5% of their weight through a low-calorie diet, and half will also lose 10% and 15% body weight.
Study: NCT03988166

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chronic Total Occlusion Revascularization
Description: Teleflex's series of study guidewires and catheters will be used to facilitate the safe and effective crossing of de novo CTOs and placement of conventional guidewires beyond the lesion via either a true lumen or subintimal pathway.

Intervention type: DEVICE
Group type: OTHER
Intervention: GuideLiner® V3 catheter, TrapLiner® catheter, Turnpike® catheter
Description: GuideLiner® V3 catheter, TrapLiner® catheter, Turnpike® catheter
Study: NCT03655925

Intervention type: DIAGNOSTIC_TEST
Intervention: plasmatic HLA-G
Description: plasmatic HLA-G by blood sample
Study: NCT03790761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREP 8.0 Curriculum
Description: The PREP 8.0 curriculum is an experiential curriculum designed to be implemented in a workshop or educational setting. Using techniques of cognitive-behavioral marital therapy and communication-oriented marital enhancement, PREP aims to help couples achieve high levels of relationship functioning and prevent marital problems. The PREP approach is based on research in the field of relational and marital health and success conducted at the University of Denver.
Study: NCT02144922

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin
Description: statin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Life style modification alone
Study: NCT03347916

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Strawberry juice as (placebo)
Description: Patients received strawberry juice 5 ml volume, one hour before induction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin Oral Solution [Neurontin]
Description: Patients received gabapentin (Neurontin oral solution 250 mg/ml, Pfizer, USA) 5 mg/kg mixed with strawberry juice to constitute 5 ml volume, one hour before induction.
Study: NCT00947661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC0912
Description: Eye drops, once daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference0912
Description: Eye drops, once daily, 12 weeks
Study: NCT01886001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: Umbilical stump care. Povidone-Iodine, USP, Swabstick Singles, applied once a day to cord stump while umbilical line(s) are in place

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Umbilical stump care. Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied once a day to cord stump while umbilical line(s) are in place

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pluronic
Description: Umbilical stump care. Pluronic gel - (F68, Polymyxin, Nystatin, Nitrofurantoin)applied once a day to cord stump while umbilical line(s) are in place

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
Study: NCT03246256

Intervention type: OTHER
Intervention: Group 1

Intervention type: OTHER
Intervention: Group 1

Intervention type: OTHER
Intervention: Group 1
Study: NCT03806283

Intervention type: PROCEDURE
Intervention: Omental Biopsy
Description: The surgeon and clinical care team will conduct the c-section to deliver the baby and the placenta as clinically indicated. After delivery, during the closing procedures, the surgeon will indicate a time for a participating Ob/Gyn physician on the study team to collect the omental bio-specimen. Omentum is frequently excised or removed for clinical reasons during surgical procedures. Omentum has small blood vessels within it that have been used for evaluation of vascular functional changes in research. The investigators wish to isolate one to three vessels of 5 to 7 cm length. The surgeon will then close and the clinical care team will resume their standard of care activities.
Study: NCT00966004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tolterodine
Description: oral
Study: NCT00774384

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NZ MenB OMV vaccine (NZ98/254)
Description: 3 doses by intramuscular injection
Study: NCT03078816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa PC Primary Cell Neurostimulator - (Model 37601)
Description: Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa RC Rechargeable Neurostimulator - (Model 37612)
Description: Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa SC Single Cell Neurostimulator (Models 37602/37603)
Description: Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS Lead - (Model 3387
Description: Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS Extension - (Models 37085/6)
Description: Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient Programmer - (Model 37642)
Description: Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Stimulator - (Model 3625)
Description: Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
Study: NCT01557647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil
Description: 0.6mg/mL treprostinil for inhalation solution. Titrated up to 12 breaths QID.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo inhalation solution
Study: NCT03731182

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: V114 pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: Prevnar 13™ pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
Study: NCT03788577

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oligonol intake
Description: Major intervention of Oligonol component , as suggested Oligonol safe dose for adults is 200mg per day.
Study: NCT03078816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: N'Vision Clinician Programmer - (Model 8840)
Description: Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
Study: NCT02679079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854
Study: NCT03078816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: N'Vision Software Application Card - (Model 8870)
Description: Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
Study: NCT01581723

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monopolar diathermy
Description: monopolar diathermy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bipolar diathermy
Description: bipolar diathermy
Study: NCT03781921

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention. Each group will conduct the same tasks and questionnaires and we will compare performances between groups.

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention. Each group will conduct the same tasks and questionnaires and we will compare performances between groups.
Study: NCT02461810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vertebral fracture surgery SpineJack®
Description: Vertebral augmentation for one osteoporotic vertebral compression fracture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon Kyphoplasty
Study: NCT01727063

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cell Therapy
Description: Intramyocardial injection of autologous bone marrow-derived cells
Study: NCT02679079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01295775

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sulodexide
Description: A (SULODEXIDE GROUP):~50 mg a day by oral route (1+1 capsules/day) for 360 days~B (PLACEBO GROUP):~Sulodexide placebo at the same schedule dosage and for the same lengths of time as group A.
Study: NCT03886259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercises (NEMEX-TJR) and pain neuroscience education
Description: 60min. of neuromuscular exercises (NEMEX-TJR) training two times a week for 3 months (12 weeks, 24 sessions). Physiotherapists will instruct and supervise the participants during the neuromuscular exercises. The aim of the neuromuscular exercise program is to restore normal movement, improve sensorimotor control, re-establishing normal motor program strategies and muscle activation.~60min. of pain neuroscience education at the beginning of intervention period and after 6 weeks. Both sessions will take 60min. and will be conducted by physiotherapists. The aim of the pain neuroscience education is to increase the pain neuroscience knowledge of the patients leading to a better understanding of their chronic pain and thereby engaging the patients in the treatment of their chronic pain and impaired function.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain neuroscience education
Description: 60min. of pain neuroscience education at the beginning of intervention period and after 6 weeks. Both sessions will take 60min. and will be conducted by physiotherapists. The aim of the pain neuroscience education is to increase the pain neuroscience knowledge of the patients leading to a better understanding of their chronic pain and thereby engaging the patients in the treatment of their chronic pain and impaired function.
Study: NCT01778556

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Metreleptin
Description: Recombinant analog of the human hormone, leptin
Study: NCT01295775

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulodexide
Description: A (SULODEXIDE GROUP):~50 mg a day by oral route (1+1 capsules/day) for 360 days~B (PLACEBO GROUP):~Sulodexide placebo at the same schedule dosage and for the same lengths of time as group A.
Study: NCT02358499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: Posaconazole will be given as a one time intravenous (IV) dose. The dose will take ninety (90) minutes to be infused and will be based on weight at the time of the visit.
Study: NCT03329703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project UPLIFT
Description: A group, telephone-based intervention for depression that uses techniques from mindfulness-based therapy and cognitive therapy. The intervention consists of 8 sessions occurring at the same time and day every week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project UPLIFT
Description: A group, telephone-based intervention for depression that uses techniques from mindfulness-based therapy and cognitive therapy. The intervention consists of 8 sessions occurring at the same time and day every week.
Study: NCT00950443

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acoustic reflection method
Description: Acoustic reflection gives the longitudinal cross-sectional area profile along airway.Based on planar acoustic wave propagating in a rigid duct connected to airway.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acoustic method and breathing/endoscopic evaluation
Description: Endoscopic evaluation done under general anaesthesia.
Study: NCT06018298

Intervention type: OTHER
Intervention: Treatment as usual (TAU)
Description: the components of treatment as usual (TAU) are summarised and assessed by the items of the DUNDRUM-3: physical health, mental health, substance misuse, problem behaviours, self care and activities of daily living, education occupation and creativity, family and intimacy.

Intervention type: OTHER
Intervention: Treatment as usual (TAU)
Description: the components of treatment as usual (TAU) are summarised and assessed by the items of the DUNDRUM-3: physical health, mental health, substance misuse, problem behaviours, self care and activities of daily living, education occupation and creativity, family and intimacy.
Study: NCT00312260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin will be prescribed at 900mg/d (300mg tid). A dose escalation schedule will be followed: one pill taken at night (\~2000h) for the first 3 days, one pill at night and one pill in the morning (\~0800h) for the second 3 days and finally, one pill at night, one in the morning and one mid-afternoon (\~1400h) for the reminder of the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: Amitriptyline will be prescribed at a dose of 10mg (qhs). A dose escalation schedule will be followed: one pill taken at night (\~2000h) for the first 3 days, one pill at night and one pill in the morning (\~0800h) for the second 3 days and finally, one pill at night, one in the morning and one mid-afternoon (\~1400h) for the reminder of the trial.
Study: NCT03788577

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03208426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole (S14)
Description: Nexium, esomeprazole 40mg bid, 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole (BQ10)
Description: Nexium, esomeprazole, 40mg bid for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin (ST14)
Description: Day 1-7 amoxicillin (Brand name: Amoxicillin Capsule) 1000mg bid for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin (ST14)
Description: Klaricid-XL, clarithromycin, 500mg, bid, for 7 days, (day 8-14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole (ST14)
Description: Flagyl, metronidazole, 500mg bid, for 7 days (day 8-14)
Study: NCT03221725

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sacrospinous ligament fixation
Description: sacrospinous ligament fixation will be applied to prevent vaginal vault prolapse
Study: NCT03066401

Intervention type: PROCEDURE
Intervention: echography
Description: The inferior vena cava and the internal jugular vein diameters were measured by echography before and after blood withdrawal during a standardized respiratory maneuver
Study: NCT00593125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levetiracetam
Description: The participants will start receiving Levetiracetam 500mg in the mornings of the first day on week 2. The dose will be titrated every third day, until the target dose of 3000mg/day is achieved by week 4. The study medication must be titrated to 3000 mg/day or to the subject's maximum tolerated dose (MTD). The physician overseeing this titration as well as all study staff will not be blind to the subject's medication administration. The medication will be discontinued over a two-week period
Study: NCT03188120

Intervention type: DRUG
Intervention: Spiriva Respimat
Description: Drug
Study: NCT05488275

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: MPFL reconstruction
Study: NCT03606304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy
Description: See previous
Study: NCT03871946

Intervention type: DIAGNOSTIC_TEST
Intervention: oral glucose tolerance test (OGTT)
Description: Implementation of OGTT: The patient was seated in a quiet room after 10-12 h of overnight fasting, and blood samples were drawn. Thereafter, 75 g glucose solution dissolved in 300 mL of water was administeredwithin 5 min. Two hours after this,another blood sample was drawn. During the test, the patient wasn't allowed to rest and eat, but not smoke.

Intervention type: DIAGNOSTIC_TEST
Intervention: oral glucose tolerance test (OGTT)
Description: Implementation of OGTT: The patient was seated in a quiet room after 10-12 h of overnight fasting, and blood samples were drawn. Thereafter, 75 g glucose solution dissolved in 300 mL of water was administeredwithin 5 min. Two hours after this,another blood sample was drawn. During the test, the patient wasn't allowed to rest and eat, but not smoke.